최종 결과
10 4월 2024
프로테옴 사이언스 plc
("Proteome Sciences" the "Company" or the "Group")
31년 2023월 XNUMX일 마감된 연도의 최종 결과
회사는 31년 2023월 XNUMX일에 종료된 회계연도의 감사 결과를 발표하게 된 것을 기쁘게 생각합니다.
하이라이트:
· 총 수익 £5.03m(2022년: £7.78m)
· Proteomic services revenues of £1.63m (2022: £2.75m)
· TMT® sales, and royalties of £3.40m (2022: £4.16m)
· Total costs of £6.65m (2022 £6.05m)
· EBITDA loss of £1.14m (2022: £2.13m)
· Adjusted EBITDA* loss of £0.92m (2022: Adjusted EBITDA* profit of 2.43만 파운드)
· Loss after tax of £2.44m (2022: profit after tax £1.33m)
· 31년 2023월 2.03일 현재 현금 보유액 £2022m(3.99년: £XNUMXm)
* EBITDA는 그룹 재무 성과의 핵심 성과 지표로 간주되는 비GAAP 회사별 측정값입니다. 조정 EBITDA는 감가상각비(사용권 자산 상각 포함), 상각비, 비경상 비용 및 직원주식 기준 지급 전 영업 이익으로 계산됩니다.
Proteome Sciences plc의 CEO인 Dr. Mariola Soehngen은 다음과 같이 말했습니다.
The second half of 2023 proved to be challenging for Proteome Sciences. The macroeconomic situation impacted on our client base and resulted in a decrease in revenues caused by the delay in the timing of services contracts. We remained in close contact with our clients over that period and the higher dynamics we have seen since the start of 2024 would appear to support the hypothesis that the market demand is returning to normal. During the second half of 2023 we set up our US lab which opened in early 2024. For US based clients who did not previously want to ship their samples to Europe we have provided a US solution and we will now be eligible for projects funded by US institutions where the funds must be spent in the US. We invested substantially in 2023 to expand our business by establishing the facility in San Diego, developing new ranges of TMT® and data-independent acquisition ("DIA") tags and launching SCP to address the growing global demand for proteomics in 2024.
The 2024 year has experienced significant customer engagement and interest in proteomics services reflected by the considerable increase in customer contact and quotations provided across multiple projects from which new contacts have been secured in the first quarter. We expect this momentum to continue throughout 2024.
For our tag business we expect the introduction of the 32plex TMTpro™ tags due in 2024 to generate strong interest in the market and significant revenues in the coming years.
Our DIA tags are being evaluated by academic partners and we have initiated discussion around licensing for commercial development that we expect to conclude during the year.
Interest in SCP has continued to grow since our launch and we expect to run more commercial projects in the near future.
In summary, we expect the investments that we have made and the new products and services we have introduced to add to and bring the business back to growth in 2024.
연례 총회 보고, 회계 및 통지:
Copies of the Annual Report and Accounts together with notice of the Annual General Meeting ("AGM") will be posted to shareholders shortly and made available on the Company's website (www.proteomics.com).
The AGM of the Company will take place at 12 noon on Thursday 16 May 2024 at Allenby Capital, 5 St Helen's Place, London, EC3A 6AB. Formal notice of the AGM will be sent to shareholders which will contain further information and the resolutions which will be proposed at this meeting.
자세한 내용은 문의하시기 바랍니다 :
|
Proteome Sciences plc 소개 (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2는 새로운 표적을 식별 및 맥락화하고 생물학적 활동의 메커니즘을 정의하기 위한 공정한 방법이며, Super-Depletion 및 TMTcalibrator™를 사용한 분석은 질병 관련 바이오마커 발견을 위해 8,500개 이상의 순환 혈장 단백질에 대한 액세스를 제공합니다. 질량 분석법을 사용한 표적 분석 개발은 표준 ELISA 분석을 사용할 수 없는 상황에서 간섭 없는 고감도 바이오마커 분석을 제공합니다.
최고 경영자의 성명서
Group revenues for the full year decreased by 35% to £5.03m (2022: £7.78m), services revenue decreased by 41% to £1.63m (2022: £2.75m) and sales and royalties attributable to TMT®/TMTpro™ reagents decreased by 18% to £3.40m (2022: £4.16m*).
* excluding the sales milestone payment of £0.87m received in 2022 under the exclusive licence and distribution agreement with Thermo Fisher Scientific.
Despite our expectation at the end of 2022 and during H1 2023 to deliver further growth in 2023, the second half of 2023 did not develop as expected. As alluded to in our investor meeting in September 2023 and announced on 30 November 2023 the challenging macroeconomic situation with weak growth, high inflation and tight monetary policy has impacted many of our clients and partners. Particularly the biotech sector was severely affected by these headwinds, exemplified by significant layoffs and reduction of R&D budgets industry wide. Also, larger customers reduced their activities in the proteomics field and postponed planned projects to 2024. Given the market requirement for our proteomic products and services we expect customer interest for our services to significantly improve during 2024, with the introduction of new next generation tags in the isobaric and isotopic field, and the output from the US lab, the Company is confident to see the business return to growth in 2024.
We have continued our planned strategic investment in both our Frankfurt and San Diego laboratories and added various instruments primarily in the US laboratory including an Orbitrap Ascend Tribrid mass spectrometer and Accelerome automated sample preparation platform. We launched single cell proteomics ("SCP") in October 2023 and are working on the first projects. In addition, we have advanced our new tag developments (isobaric and isotopic) and expect to launch both near term plus develop next generation isotopic tags.
Total costs, excluding finance costs, rose to £6.65m (2022: £6.05m) which has resulted in an operating loss of £1.62m (2022: operating profit of £1.73m) and a net loss of £2.44m (2022: profit after tax of £1.33m). Cash reserves at the year-end were at £2.03m (2022: £3.99m).
| 2023 | 2022 |
| £'000 | £'000 |
수익 | 5,028 | 7,780 |
매출 총 이익 | 1,647 | 4,767 |
관리비 * | (3,268) | (3,039) |
EBITDA | (1,137) | 2,125 |
기타 비현금 항목 및 비반복적 비용 | 218 | 303 |
조정 EBITDA | (919) | 2,428 |
Adjusted EBITDA (a non-GAAP Group specific measure (see Note 3) which is considered to be a key performance indicator of the Group's financial performance) decreased by £3.35m year on year mainly due to lower revenues while costs have increased due to additional staff and the expansion to the U.S.
*감가상각비 £0.5m 포함(2022년: £0.4m)
서비스
It was a challenging year in our service business in 2023. As in previous years, the US is by far our most significant market in terms of biopharma companies who outsource their proteomic services to Contract Research Organisations ("CROs") such as Proteome Sciences. Unfortunately, the biopharma market especially in the US was marked by employee layoffs in 2023. According to Fierce Biotech, a company that provides news, analysis and data relating to the biotech sector, biopharma layoffs were 57% up in 2023. This has been confirmed by other Life Science provider companies in their public reporting. The significantly reduced level of financing in biopharma resulted in workforce reductions affecting 187 organisations in 2023. 우리는 in contact and discussing projects with 38 of these that were primarily focused in proteomic pre-clinical and clinical research. Projects were either cancelled before samples were shipped, or significantly delayed pending future financing rounds. This seriously affected our ability to win business.
During the first half of 2023 orders received and sales were performing to plan halfway through the year, but this slowed significantly in the second half of 2023. Projects under discussion in the first half of 2023 did not arrive in the second half of the year, and initial discussions on new projects slowed. A considerable client outreach effort was initiated at the start of the second half of the year to offset this slowdown and that did uncover new project opportunities that are currently under discussion, so we believe the worst of the 2023 slowdown is behind us now. In the US the main focus was our investment in the new laboratory and preparing the market for the pending launch of the SCP service. Over and above this additional outreach, we continued our presence in various conferences and exhibitions throughout 2023 in both the US and Europe, combining these events with local client visits when in the close vicinity.
The news that the company has invested in a new US based laboratory in San Diego was very well received by existing clients who said they will use our new facility from 2024 onwards, and from new customers who will use us for the first time as a result of the new laboratory. It was not unexpected to hear that all clients preferred a local facility to avoid excessive shipping charges to get their samples into Europe, and to avoid any customs issues to clear samples through German importation control. Equipping the new lab with a latest generation mass spectrometer was also seen as giving us a distinct advantage over more local competition. In addition, our US entity Proteome Sciences US Inc enables the company to partake in National Institute of Health ("NIH") and other US government sponsored grants.
In the European section of our business, we concluded all the work connected with a large Europe based clinical trial through the year. From a European perspective the UK continues to be the more active component, and we have picked up several important clients requiring proteome analysis in projects destined for, or in clinical trials.
In general, the biopharma investment slowdown did affect our business more than we expected at the start of 2023, but given the investment in new equipment, facilities and new product offerings commercially we remain confident to get back on our growth trajectory in 2024.
라이센스
Income from licensing our intellectual property assets remains a key contributor to revenue, primarily through the TMT® and TMTpro™ reagents. We retain a portfolio of patents and applications covering biomarkers and reagents which we continue to monitor for commercialisation potential. As the field around use of blood proteins in diagnosis of Alzheimer's disease, other neurodegenerative disorders and many cancers our patented biomarkers may prove critical in development of novel diagnostic tests opening up additional licensing opportunities.
탠덤 질량 태그®
In line with other parts of the business the revenue from TMT® and TMTpro™ reagent sales decreased 18% relative to 2022 (excluding milestone payment). In part this is attributable to the full year effect of a one-off adjustment to running royalties following expiry of the TMT1 patent family in September 2022 but also reflects weaker markets for the tags globally. A range of factors are likely to have impacted tag sales including the general macroeconomic situations, the use of alternative mass spectrometry methods such as data independent acquisition and the delay of purchases pending introduction of the 32plex TMTpro™ tags due in 2024.
We are working with our licensee Thermo Fisher Scientific to address the market challenges and are excited at the prospects for the extended TMTpro™ reagents that now allow large discovery projects to be completed in a single experiment, greatly improving the coverage and quantitative precision and accuracy available to researchers.
뇌졸중 바이오마커
Our two licensees Randox Laboratories and Galaxy CCRO ("Galaxy") have made progress with their clinical trials during 2023. In connection with Galaxy's initiation of a first clinical study in Europe we received a milestone. Galaxy is a US based clinical contract research organisation, which is developing a point of care test for the diagnosis and timing of stroke onset in order to guide the use of specialist thrombolytic treatment. Under the terms of the licence with Galaxy we have received equity in Galaxy as an initial fee in 2019 and similarly the milestone in 2023 was also satisfied in equity. As a result of this we own a minority stake in Galaxy and under the licence we are entitled to subsequent development milestones and a running royalty on any product sales. We expect more news to come during 2024 with the possibility for further milestones relating to trial completion and product launches on the horizon.
리써치
During the year we have focused our research efforts on improving our processes and have successfully achieved a significant improvement in our sample preparation processes enabling us to increase our capacities by 50%. The new workflows are also simpler, more robust and deliver equivalent performance within the same budget. In parallel, we continued to optimise workflows for Single Cell Proteomics. Over the year we were able to improve coverage so that we can attain quantification for approximately 1,500 proteins per cell in studies where we measure 576 individual cells. Overall performance is stable across different cell types and we are now beginning our first commercial activities with the SysQuant®-SCP service operating from our Frankfurt laboratory.
We also continue research to develop new reagents for proteomics and this resulted in our producing a set of non-isobaric tags for multiplexing of data-independent acquisition ("DIA") studies. The tags are being evaluated by academic partners and we have initiated discussions around licensing for commercial development that we expect to conclude during the year. We also completed the development of the extended set of TMTpro™ reagents and look forward to their introduction to our services in the first half of 2024. We continue to innovate in chemistry and will be working on ancillary products to add new functionality for TMTpro™ enabled studies through a sponsored research project.
운영 환경
We started the year 2023 with a strong order book. Our service business developed positively in H1 2023 with 19% increase over the same period in 2022 - a trend which could not be sustained in H2 2023. The TMT® business remained flat in the first half of the year and decreased by 18% year on year. Next to the macroeconomic changes which have influenced our clients and us negatively the expectation of the new 32plex isobaric tags might also have played a role in the cautious ordering of tags.
To address the growing DIA market, we have developed a totally new line of isotopic tags which we aim to partner with a strong distribution partner.
SCP as our new service was launched in October 2023 and we have started first projects in partnership with academic key opinion leaders and our long-term customers. The roll out of this service is expected to unfold in 2024 when customer projects will be delivered from the Frankfurt lab.
The US lab has been opened in January 2024, and was met with good interest primarily in the US market where we plan to address the customers who have had reservations to ship samples to the EU. With the lab in San Diego, one of the largest biotechnology and pharmaceutical research hub globally, we have addressed these concerns and are starting customer projects in 2024.
At the end of a difficult year for our business and following the substantial strategic investments that have been made for the future, we would like to thank all our teams for their contribution, passion and hard work. We expect the macroeconomic trends to improve in the course of 2024 and these should impact positively on our business.
Outlook
We invested substantially in 2023 to expand our business by establishing the facility in San Diego, developing new ranges of TMT® and DIA tags and launching SCP to address the growing global demand for proteomics in 2024.
The 2024 year has experienced significant customer engagement and interest in proteomics services reflected by the considerable increase in customer contact and quotations provided across multiple projects from which new contacts have been secured in the first quarter. We expect this momentum to continue throughout 2024.
For our tag business we expect the introduction of the 32plex TMTpro™ tags due in 2024 to generate strong interest in the market and significant revenues in the coming years.
Our DIA tags are being evaluated by academic partners and we have initiated discussion around licensing for commercial development that we expect to conclude during the year.
Interest in SCP has continued to grow since our launch and we expect to run more commercial projects in the near future.
In summary, we expect the investments that we have made and the new products and services we have introduced to add to and bring the business back to growth in 2024.
We would like to thank our shareholders and team for their continuing support, and we look forward to communicating renewed progress in 2024.
마리올라 쇤겐 박사 최고 경영자(CEO) 9 4월 2024 |
전략 보고서
사업 검토
그룹의 주요 활동에는 단백질 바이오마커 연구 및 개발이 포함됩니다. 응용 단백질체학 분야의 선두주자로서 당사는 고감도 독점 기술을 사용하여 진단, 예후 및 치료 응용을 위해 생물학적 시료에서 차별적으로 발현되는 단백질을 검출하고 특성화합니다. 또한, TMT 기술을 발명, 개발하였습니다.® and TMTpro™, and manufacture these small, protein-reactive chemical reagents which are sold for multiplex quantitative proteomics under exclusive license by Thermo Fisher Scientific.
Proteome Sciences는 단백질 바이오마커의 식별, 검증 및 적용을 위한 계약 연구 서비스를 제공하는 주요 제공업체입니다. 우리의 고객은 주로 제약 및 생명공학 회사이지만 학술 연구를 포함한 다른 분야에도 서비스를 수행합니다. 우리는 많은 고객의 요구를 충족하는 여러 가지 잘 확립된 워크플로우를 보유하고 있지만 가능한 한 과학 중심의 비즈니스 초점을 유지하고 새로운 분석 방법, 새로운 시약 및 데이터 분석 도구를 개발하여 제공할 수 있는 연구 유형에 더 큰 유연성을 제공합니다. . 당사의 계약 서비스 제공은 여전히 질량 분석 기반 단백질체학에 중점을 두고 있으며, 제약 산업이 유전체학을 넘어 생물학적 지식을 확장하려고 함에 따라 이는 약물 개발 프로젝트에서 더욱 광범위하게 구현되고 있습니다. 이러한 서비스는 약물 개발 프로세스와 완전히 연계되어 있으며, 임상 시험 지원 및 체외에서 진단 및 독점 생물정보학 기능을 포함합니다.
2023년 진행 상황
서비스 사업 성장
As in all sectors of technology-based sales, no organisation can stand still and offer the same services year in and year out. As ligand binding technologies like multiplex ELISA expand both antibody and aptamer arrays to cover more proteins per run, thereby more closely compete with traditional proteomic analysis by mass spectrometry, we must take our services deeper into the proteomic field.
Single Cell Proteomics is a good example of how the company is moving forward, by using mass spectrometry to achieve protein detection levels currently several orders of magnitude greater than ELISA based technologies can achieve at this time. Another clear application area for mass spectrometry is in detection of more post translational modifications on the proteins detected in a more conventional run. We see an increasing need from biopharma to detect post translational modified peptides and proteins as end-point biomarkers in a clinical trial. This can provide ongoing business via classical protein Discovery based projects and, more importantly as the drug progresses into clinical trials, a Targeted assay under Good Clinical Laboratory Practice ("GCLP") laboratory standards. Clients have informed us that we are one of a few CRO's that they have identified who can take a research project now through to clinical reporting base in the future under more stringent GCLP standards. Furthermore, we continue to meet both new and current clients to discuss their upcoming proteomic needs and how we can help them. As protein experts, clients value our thoughts and processes on how we can solve their problems. Proteome Sciences will be expanding its services to include these 32 tags by end H1 2024, thereby having a head start on other CRO's who will have to wait for the new tags to be available from Thermo Fisher Scientific.
Finally, we have made a significant step by investing in our US laboratory. This will make it easier for current US clients to ship samples to us, and it removes the barrier for new clients to do the same. These new clients will be biopharma but will also address the considerable academic market. Many academic institutes could not use our Frankfurt facility because their grant money could only be spent in the US. Proteome Sciences US Inc also enables the company to participate in NIH/US Government grants as a US entity, employing US employees and have a US based footprint. With the latest generation mass spectrometer in the San Diego lab, we are better placed than the local providers.
핵심 프로테옴을 넘어 확장
We have been delivering deep analysis of post-translational modifications through our SysQuant® phosphoproteomics workflows for many years and introduced new methods for analysis of protein ubiquitylation more recently. These two methods have been used across many different types of studies enabling our customers to better understand how their drug targets fit into the wider biological context, as well as providing deeper insights into the mechanism of action of their experimental drugs. In 2023 we started to expand our coverage to include additional modifications relevant to a range of disease areas that were previously poorly served by traditional proteomics methods. We continue to evaluate the potential to add further protein modifications to our repertoire, along with adding additional analytes in the metabolic space where the same mass spectrometry platforms can be deployed.
단일 세포 단백질체학
Our launch of Single Cell Proteomics services in October 2023 followed an intensive development process reflecting the large technical challenge of working with such limited material. We have now initiated several biological studies with academic collaborators to demonstrate different aspects of the technology as well as a proof-of-concept study with one of our long-term customers. Critical to developing SCP is the downstream data analysis and visualization. We have been working on an in-house tool for streamlining data quality assessment, pre-processing and statistical analysis that allows us to identify cellular diversity based on the expression profiles of over 1,000 proteins per cell. Interest in SCP has continued to grow since our launch and we expect to run our first commercial projects in the near future.
Tandem Mass Tag 현황® 제품 포트폴리오
During 2023 we have been working on the largest extension of TMT™ multiplexing as we increase the current 18plex tags to 32plex. This was in response to market demand as the need to use more samples in proteomics studies is being widely recognised. Whilst many groups have been moving towards data-independent acquisition methods to gain throughput, this has been at the cost of some analytical precision and we believe that introduction of an additional 14 channels will re-balance the demand for TMTpro™ reagents which still provide the greatest combination of quantitative precision and, when combined with our patented MS3 acquisition methods, accuracy. Commercial stocks of the additional 14 tags have been synthesized and we are working with our licensee Thermo Fisher Scientific to optimise the mass spectrometry acquisition methods. We are introducing 32plex workflows to our standard proteomics services which will be available ahead of the wider commercial launch of the reagents.
뇌졸중 바이오마커
We currently have two licensees to our stroke biomarkers and both have been engaged in clinical trials of their respective tests during 2023. Randox Laboratories have a long-running trial based in the UK nearing completion and results are expected during 2024. We would hope that a product approval and launch may then follow swiftly, at least for the European market. Our other licensee, Galaxy CCRO, continues to operate in stealth mode, with a preliminary clinical trial of the GSTP marker initiated in Glasgow during the second half of 2023. Galaxy have indicated they expect a read-out of the Rhesus trial during 2024 and this will inform decisions around a full regulatory trial both in Europe and the US. We own a minority stake in Galaxy and under the license we are entitled to subsequent development milestones and a running royalty on any product sales.
특허 출원 및 재산권
During the year 2023 23 new patents were issued across five different families. Of these 6 related to the TMTpro™ reagents and methods of use and 6 related to biomarkers for Alzheimer's disease and cancer. One new patent application was submitted relating to new isotopic tags for data independent acquisition mass spectrometry. Overall costs of maintaining the patent estate were slightly lower than in 2022 due to expiry of several early TMT patents.
전략적 평가
We have used 2023 to further implement our strategy of organic growth. In particular we have:
- Addressed the growing DIA market by developing a totally new line of isotopic tags which we will licence with a strong distribution partner.
- Worked on the life cycle management of TMT by developing 32plex isobaric tags.
- Launched SCP in October 2023 as our new service and have started first projects. The roll out of this service is expected to unfold during 2024 when customer projects will be delivered from the Frankfurt lab.
- Opened the US lab in January 2024.
재무 검토
결과 및 배당금
핵심 성과 지표("KPI")
● 이사들은 수익, 조정 EBITDA, 세전/세후 이익이 그룹 성과를 측정하는 데 중요하다고 생각합니다. 그룹의 성과는 CEO 성명서에 명시되어 있습니다.
● The directors believe that the Group's rate of cash expenditure and its effect on Group cash resources are important. Net cash outflows from operating activities for 2023 were £0.48m (2022: net cash inflows of £2.14m). The costs in 2023 were higher when compared to 2022 due to the investment in our San Diego site, development of next generation tags and the launch of SCP. We suffered from lower revenues in biomarker services and TMT® as compared to 2022. Cash at 31 December 2023 was £2.03m (31 December 2022: £3.99m).
● In 2023 service revenues decreased by 41% to £1.63m (2022: £2.75m). As a proportion of total group revenue (excluding the milestone revenue) service revenues in 2023 was 32% compared to 40% in 2022.
재무 성과
For the twelve-month period ended 31 December 2023 revenue decreased 35% to £5.03m (2022: £7.78m)
● Licences, sales and services revenue decreased 27% to £5.03m (2022: £6.91m (adjusted for the milestone)). This is comprised of two revenue streams: TMT® related revenue and Proteomic (Biomarker) Services. Sterling values of our sales and royalties received for TMT® tags decreased by 18% to £3.40m (2022: £4.16m)
● Adjusted EBITDA decreased to (£0.92m) (2022: £2.43m)
● The loss after tax was £2.44m (2022: profit after tax of £1.33m)
과세
서비스 사업의 성격 변화로 인해 상업 활동에 더 중점을 두게 되면서 2023년에 사용 가능한 R&D 세액공제를 완전히 평가하지 않았으며 해당 금액은 합리적으로 보장되는 경우에만 인식됩니다.
비용 및 사용 가능한 현금
● The Group maintained a positive cash balance in 2023 and continues to seek improved cash flows from commercial income streams. Due to lower revenues and higher operating costs year on year, the Group had a negative cash flow in the year. Administrative expenses in 2023 were £3.27m (2022년: £3.04m)
● 올해 인건비는 £ 3.35m (2022년: £3.12m) 중 £0.22m는 주식 기준 결제 비용이었습니다(2022년: £0.30m).
● £0.44m의 임대료에 대한 수수료가 없는 부동산 비용은 이상 previous years (2022: £0.16m) also including property costs for the lab in San Diego
● 금융 비용은 회사의 주요 투자자 두 곳으로부터의 대출금 이자 및 리스 이자에 관련됩니다. 비용 £0.80m보다 높았습니다. 전년도(2022년: £0.47m)
● 거래 및 기타 미지급금은 £0.63m입니다(2022년: £0.82m).
● 매출채권 및 기타 미수금은 0.96만 파운드(2022년: 1.44만 파운드)였습니다.
● Cash at the year end was £2.03m (2022: £3.99m)
주요 위험 및 불확실성
사업화 활동
It is uncertain whether our range of contract proteomic services will generate sufficient revenues for the Group ultimately to be successful in an increasingly competitive commercial market which generally favours companies with a broader technology platform than our own. Similarly, our increased capacities and the opening of our US laboratory create a risk that we do not generate sufficient orders to make our commercial activities profitable.
위험 관리: 그룹은 편견 없는 발견 실험의 적용 범위를 확대하고 단일 세포를 포함한 매우 작은 샘플의 분석 역량을 확대하여 단백질체학 서비스 제공을 확대하고 더 많은 직원 시간을 투자하여 자체 판매에 투자함으로써 이러한 위험을 관리하려고 노력해 왔습니다. 주요 상업 지역에서 직접적인 비즈니스 개발 활동을 수행하고 속도, 비용 및 품질을 목표로 하는 기존 서비스 기반 지표를 채택합니다.
Adding new services bears the risk that competitors are already more advanced, and it will be difficult to find and retain new customers.
위험 관리: 우리는 단일 세포 단백질체학을 위해 우리가 개발하고 있는 기술이 시장에서 높은 수요를 갖고 있으며 따라서 많은 플레이어가 수요를 충족할 수 있는 충분한 여지가 있다고 믿습니다. 또한, Proteome Sciences는 TMT의 소유자로서 USP(Unique Selling Point)를 보유하고 있습니다.® 이는 경쟁업체에 비해 많은 이점(비용 관리 포함)을 제공합니다.
핵심 인력에 대한 의존도
그룹은 경쟁이 치열한 제한된 수의 우수한 과학, 상업 및 관리 인력을 보유하는 능력에 달려 있습니다. 그룹은 핵심 인력과 전통적인 고용 계약을 체결했으며 직원 이직률은 낮지만 1년에 2023건의 사임이 입증된 것처럼 이들의 유지를 보장할 수 없습니다.
위험 관리: 그룹은 프로젝트가 어느 한 개인에게 의존하지 않도록 작업을 조직하는 정책을 가지고 있으며, 실험실 직원에 대한 강력한 관리 감독 및 지원을 받고 있습니다. 또한 보수 패키지, 성과 관련 보너스 지급, 주식 옵션 부여 기회에 대한 연간 역할 기반 검토를 통해 유지를 추구합니다.
투자 제한
TMT의 매출 및 로열티® have historically been key to revenue and working capital for the group to invest in the business. We are still reliant on TMT® 우리 수익의 대부분에 대한 판매 및 로열티와 비즈니스 성장에 투자할 운전 자본은 여전히 제한적입니다.
Management of Risk: In addition to previous cost reduction and ongoing containment measures which have significantly changed the cost profile of the business over the last years, we also actively engage with our major creditors to manage the Company's debt.
경쟁과 기술
국제 생명과학 분야는 빠르고 실질적인 기술 변화를 겪고 있습니다. 다른 사람의 개발로 인해 그룹의 서비스 제공 및 연구 활동이 쓸모없게 되거나 경쟁력이 떨어지지 않을 것이라는 보장은 없습니다. 단백질체학은 제약 산업의 수요 증가가 서비스 제공업체 역량의 성장보다 앞서 있는 성장 영역으로 남아 있습니다.
위험 관리: 그룹은 서비스 사업이나 연구 역량의 생존 가능성에 영향을 미칠 수 있는 기술 개발을 모니터링하는 고도로 숙련된 연구 과학자와 고위 관리 직원을 고용하고 있습니다. 이는 과학 출판물에 대한 접근, 컨퍼런스 참석, 다른 조직과의 협력을 통해 달성됩니다.
라이센스 계약
그룹은 계속해서 새로운 발견과 제품에 대한 XNUMX차 라이센스를 제XNUMX자에게 제공할 계획이지만 그러한 라이센스 계약이 성공할 것이라는 보장은 없습니다.
위험 관리: 그룹은 숙련된 관리 팀이 수행하는 제안된 연구 프로젝트의 과학적, 상업적 타당성에 대한 철저한 평가를 통해 이 위험을 관리합니다. 전체 연구 프로젝트 수를 줄이고 가용 자원을 재분배함으로써 위험도 감소했습니다.
특허 출원 및 재산권
The Group seeks patent protection for identified protein biomarkers which may be of diagnostic, prognostic or therapeutic value, for its chemical mass tags, and for its other proprietary technologies. The successful commercialisation of such biomarkers, chemical tags and proteomic workflows is likely to depend on the establishment of such patent protection. However, there is no assurance that the Group's pending applications will result in the grant of patents, that the scope of protection offered by any patents will be as intended, or whether any such patents will ultimately be upheld by a court of competent jurisdiction as valid in the event of a legal challenge. If the Group fails to obtain patents for its technology and is required to rely on unpatented proprietary technology, no assurance can be given that the Group can meaningfully protect its rights. All patents have a limited period of validity and competing products may be sold by third parties on expiry in each territory. The final TMT1 patent expired in the US in September 2022. This was the last case with broad claims to the field of isobaric tagging, but the patents covering the TMT® and TMTpro™ products themselves, along with several proprietary methods such as TMTcalibrator™ and MS3 quantification remain in force. Whilst the expiration of the earliest TMT patent results in a reduced royalty rate under the exclusive licence and distribution agreement with Thermo Fisher Scientific, we do not expect further royalty reductions in 2024 and beyond. We continually monitor the implications of patent expiry and have not seen any generic isobaric tags enter the markets so far.
위험 관리: 그룹은 제한적이지만 경험이 풍부한 특허 역량을 내부적으로 보유하고 있으며, 외부 조언을 통해 보완하고 있으며, 특허 출원을 제출하기 전에 특허 가능한 자료의 공개를 방지하기 위한 통제 수단을 확립했습니다. 기존 특허 포트폴리오의 유지 관리는 지속적인 비용이 인지된 가치에 비례하는지 확인하기 위해 XNUMX년마다 검토됩니다. 우리는 가능하다면 개선된 화학 태그와 우수한 바이오마커 패널에 대한 특허를 취득하여 독점 기술의 가치를 연장하고자 하며, TMT와 같은 라이선스 제품의 시장 점유율을 모니터링하여 특허 만료의 영향을 모니터링합니다.® 및 TMTpro™.
섹션 172 성명
이사회는 회사법 제172(1)항에 따른 의무를 수행할 때 그룹의 더 넓은 이해관계자의 중요성과 그들이 고려하는 방식으로 행동할 의무를 인식합니다. 선의로 구성원 전체의 이익을 위해 회사의 성공을 촉진할 가능성이 가장 높으며, 그렇게 함으로써 무엇보다도 다음 사항을 고려합니다.
(a) 장기적으로 어떤 결정으로 인해 발생할 수 있는 결과,
(b) 회사 직원의 이익,
(c) 공급업체, 고객 및 기타 사람들과 회사의 비즈니스 관계를 강화해야 할 필요성,
(d) 회사 운영이 지역사회와 환경에 미치는 영향,
(e) 회사가 높은 수준의 사업 행위에 대한 평판을 유지하는 것이 바람직하다는 것, 그리고
(f) 회사의 구성원들 사이에서 공정하게 행동할 필요성.
이사회는 모든 결정이 장기적인 관점을 염두에 두고 내려진다고 생각하며 이러한 결정은 회사 직원의 이익, 공급업체, 고객, 지역 사회 및 회사가 운영되는 환경과의 관계를 고려해야 한다는 점을 이해합니다. 나이사회는 이러한 요구 사항이 회사 웹사이트에서도 찾을 수 있는 기업 지배 구조 선언문에서 다루어지고 있다는 견해를 가지고 있습니다. www.proteomics.com.
이 성명서의 목적을 위해 취해진 결정에 대한 자세한 설명은 전략적으로 중요한 결정으로 제한됩니다. 이사회는 해당 연도에 내려진 두 가지 결정이 다음과 같다고 생각합니다. 이 범주는 내부 및 외부 이해관계자 모두를 충분히 고려하여 다음과 같이 만들어졌습니다.
연례 총회(AGM)
The Board encourages engagement with the Group's shareholders and took the decision in 2023 to hold the AGM as both an in person and virtual meeting therefore improving accessibility.
Investment in a US laboratory
The board considers the decision to open a US laboratory facility an important investment in the future of the organisation. With a large percentage of interest in the organisation's services originating from the US the new San Diego laboratory will expand the reach of the organisation to provide services to both existing and new customers in the US.
이사회 순서
코브햄 하우스
다운사이드 브리지 로드
Cobham
써리 KT11 3EP
Victoria Birse
회사 비서
9 4월 2024
연결 손익 계산서
31년 2023월 XNUMX일로 종료되는 연도에 대해
|
|
|
| |
주의 사항 | 연말 31 12월 2023 |
| 연말 31 12월 2022 | |
|
| £'000 |
| £'000 |
수익 | ||||
라이센스, 판매 및 서비스 | 5,028 | 7,780 | ||
수익 - 총계 | 5,028 | 7,780 | ||
매출원가 | (3,381) | (3,013) | ||
매출 총 이익 | 1,647 | 4,767 | ||
관리비 | (3,268) | (3,039) | ||
운영 (손실) / 이익 | (1,621) | 1,728 | ||
금융 비용 | (797) | (473) | ||
(손실)/과세전 이익 | (2,418) | 1,255 | ||
| ||||
세금(요금)/크레딧 | (25) | 70 | ||
(손실) / 연간 이익 | (2,443) | 1,325 | ||
(손실)/주당 이익 | ||||
Basic 희석 | 3 | (0.83p) (0.83p) | 0.45p 0.43p |
연결포괄손익계산서
31년 2023월 XNUMX일로 종료되는 연도에 대해
|
| 연말 |
| 연말 | |||
|
| 31년 2023월 XNUMX일 |
| 31 December 2022 | |||
|
| £'000 |
| £'000
| |||
(손실) / 연간 이익 | (2,443) | 1,325 |
| ||||
|
| ||||||
기타 포괄 손익 |
| ||||||
손익으로 재분류되거나 재분류될 수 있는 항목: |
| ||||||
해외사업장 환산차이 | (41) | 158 |
| ||||
확정급여형 연금제도의 재측정 | 43 | 145 |
| ||||
(손실)/당해 이익 및 총포괄손익 | (2,441) | 1,628 |
| ||||
Attributable to owners of parent | (2,441) | 1,628 |
| ||||
연결 대차 대조표
31 년 2023 월 XNUMX 일 기준
|
| 2023 | 2022 |
|
| £'000 | £'000 |
비유동 자산 |
|
|
|
친선 |
| 4,218 | 4,218 |
재산, 식물 및 장비 |
| 551 | 444 |
사용권 자산 |
| 2,525 | 873 |
|
| 7,294 | 5,535 |
유동 자산 |
|
|
|
재고 |
| 837 | 901 |
매출 채권 및 기타 채권 |
| 955 | 1,443 |
계약 자산 |
| 345 | 560 |
현금 및 현금성 자산 |
| 2,027 | 3,994 |
|
| 4,164 | 6,898 |
총자산 |
| 11,458 | 12,433 |
유동 부채 |
|
|
|
매입 채무 및 기타 채무 |
| (629) | (823) |
계약 부채 |
| (1) | (104) |
차입금 |
| (11,235) | (11,262) |
리스 부채 |
| (609) | (300) |
|
| (12,474) | (12,489) |
순유동 부채 |
| (8,310) | (5,591) |
비유동 부채 |
|
|
|
리스 부채 |
| (1,631) | (353) |
연금 조항 |
| (419) | (434) |
비유동 부채 |
| (2,050) | (787) |
총 부채 |
| (14,524) | (13,276) |
순부채 |
| (3,066) | (843) |
공평 |
|
|
|
주식 자본 |
| 2,952 | 2,952 |
프리미엄 공유 |
| 51,466 | 51,466 |
주식기준보상준비금 |
| 4,713 | 4,495 |
합병준비금 |
| 10,755 | 10,755 |
번역예비 및 기타예비 |
| (10) | 31 |
이익잉여금 |
| (72,942) | (70,542) |
총 적자 |
| (3,066) | (843) |
연결자본변동표
31년 2023월 XNUMX일로 종료되는 연도에 대해
|
공유 자본 | 공유 프리미엄 계정 | 공유 기반 결제 비축 |
번역 비축 |
합병 비축 |
잉여금 오프 | 지배기업의 소유주에게 귀속되는 자본 |
금액 (적자) |
£'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | |
1년 2022월 XNUMX일 | 2,952 | 51,466 | 4,193 | (128) | 10,755 | (72,013) | (2,775) | (2,775) |
올해의 이익 | - | - | - | - | - | 1,325 |
1,325 | 1,325 |
해외사업장 환산차이 | - | - | - | 158 | - | - |
158 | 158 |
확정급여형 연금제도의 재측정 | - | - | - | - | - | 145 | 145 | 145 |
|
|
|
|
|
|
|
|
|
당해년도 이익 및 총포괄비용 | - | - | - | 158 | - | 1,470 |
1,628 |
1,628 |
주식기준보상에 대한 자기자본에 대한 신용 | - | - | 303 | - | - | - |
303 | 303 |
31년 2022월 XNUMX일 | 2,952 | 51,466 | 4,495 | 31 | 10,755 | (70,542) |
(843) | (843) |
연결자본변동표
31년 2023월 XNUMX일로 종료되는 연도에 대해
공유 자본 | 공유 프리미엄 계정 | 공유 기반 결제 비축 |
번역 비축 |
합병 비축 |
잉여금 오프 | 지배기업의 소유주에게 귀속되는 자본 |
금액 (적자) | |
£'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | |
1년 2023월 XNUMX일 | 2,952 | 51,466 | 4,495 | 31 | 10,755 | (70,542) | (843) | (843) |
|
|
|
|
|
|
|
| |
올해의 손실 | - | - | - | - | - | (2,443) |
(2,443) | (2,443) |
해외사업장 환산차이 | - | - | - | (41) | - | - |
(41) | (41) |
확정급여형 연금제도의 재측정 | - | - | - | - | - | 43 | 43 | 43 |
|
|
|
|
|
|
|
| |
당해 연도의 손실 및 총포괄손익 | - | - | - | (41) | - | (2,400) |
(2,441) |
(2,441) |
주식기준보상에 대한 자기자본에 대한 신용 | - | - | 218 | - | - | - |
218 | 218 |
|
|
|
|
|
|
|
| |
31년 2023월 XNUMX일 | 2,952 | 51,466 | 4,713 | (10) | 10,755 | (72,942) | (3,066) | (3,066) |
|
|
|
|
|
|
|
|
|
연결 현금 흐름표
31년 2023월 XNUMX일로 종료되는 연도에 대해
| 그룹 |
| 그룹 |
| |
| 연말 |
| 연말 |
| |
| 31 12월 |
| 31 12월 |
| |
| 2023 |
| 2022 |
| |
| £'000 | £'000 | |||
|
|
|
| ||
(손실)/세후 이익 | (2,443) | 1,325 | |||
다음에 대한 조정 : | |||||
금융 비용 | 797 | 437 | |||
유형 자산의 감가 상각 | 123 | 106 | |||
임대 감가상각 | 361 | 178 | |||
세금(신용)/요금 | 25 | (70) | |||
주식기준보상비용 | 218 | 303 | |||
운전 자본 이동 전 영업 현금 흐름 |
(919) |
2,279 | |||
재고 감소 | 63 | 187 | |||
채권의 감소/(증가) | 704 | (920) | |||
(감소)/미지급금의 증가 | (298) | 293 | |||
(감소) 충당금 증액 | (15) | 80 | |||
외국환 | 9 | 151 | |||
현금(사용)/영업에서 발생 | (456) | 2,070 | |||
세금(납부)/수취 | (25) | 70 | |||
영업활동으로 인한 순현금(유출)/유입 |
(481) |
2,140 | |||
투자 활동으로 인한 현금 흐름 | |||||
Lease upfront payment | (187) | - | |||
재산, 식물 및 장비 구매 | (237) | (319) | |||
Loans advanced to subsidiary undertakings | - | - | |||
투자활동으로 인한 순현금(유출)/유입 | (424) | (319) | |||
금융 활동 | |||||
리스 지불 | (238) | (209) | |||
부채 상환 | (824) | - | |||
재무활동으로 인한 순현금유출 | (1,062) | (209) | |||
현금 및 현금 등가물의 순증가 | (1,967) | 1,612 | |||
연초 현금 및 현금 등가물 | 3,994 | 2,387 | |||
환율 변동의 영향 | - | (5) | |||
연말 현금 및 현금 등가물 | 2,027 | 3,994 | |||
재무 정보에 대한 참고 사항
1. 준비의 기초
이 문서에 명시된 재무 정보는 31년 회사법 2023항의 의미 내에서 2022년 434월 2006일 또는 31년에 종료된 회사의 법정 계정을 구성하지 않습니다. 2023년 9월 2024일에 종료된 연도의 법정 계정은 다음이 승인했습니다. 31년 2023월 2022일자로 이사가 독립 감사관에 의해 보고되었습니다. 498년과 2년 498월 3일에 종료된 연차 보고서 및 재무제표에 대한 독립 감사인의 보고서는 적합하지 않았으며 2006년 회사법 XNUMX(XNUMX) 또는 XNUMX(XNUMX)에 따른 진술을 포함하지 않았습니다.
31년 2022월 31일에 종료된 연도의 법정 계정이 회사 등록 기관에 제출되었습니다. 2023년 11월 3일에 종료된 연도의 법정 계정은 적절한 시기에 회사 등록국에 전달되고 곧 주주들에게 게시될 예정이며, 그 후 Coveham House, Downside Bridge Road, Cobham, Surrey에 있는 회사 등록 사무실에서 확인할 수 있습니다. KTXNUMX XNUMXEP 및 당사 홈페이지에서 http://www.proteomics.com/investors.
본 결과에 제시된 재무정보는 다음의 인식 및 측정원칙을 사용하여 작성되었습니다. 영국은 회사법 2006의 요구 사항에 따라 국제 회계 표준을 채택했습니다. 이 결과에 채택된 회계 정책은 표시된 모든 연도에 일관되게 적용되었으며 31년 2022월 1일로 종료되는 회계연도의 재무제표 작성에 사용된 정책과 일관됩니다. 단, 다음 회계연도에 유효한 새로운 기준 및 해석과 관련된 정책은 제외됩니다. 그룹이 채택한 기타 새로운 기준서, 개정사항 및 기존 기준서에 대한 해석은 재무제표에 중요한 영향을 미치지 않으므로 기재되지 않았습니다.
2. 유동성 및 계속 기업
그룹의 비즈니스 활동은 향후 개발, 성과 및 위치에 영향을 미칠 수 있는 요소와 함께 CEO의 성명서 및 전략 보고서에 명시되어 있습니다. 연결실체의 재무상태, 현금흐름, 유동성상태 및 차입조건은 재무제표 주석, 특히 연결현금흐름표에 기재되어 있습니다.
Notwithstanding net liabilities of £3,066k these financial statements have been prepared on the going concern basis which remains reliant on the Group achieving an adequate level of sales in order to maintain sufficient working capital to support its activities. The directors have reviewed the Company's and the Group's going concern position, taking account of current business activities, budgeted performance and the factors likely to affect its future development, as set out in the Annual report, and including the Group's objectives, policies and processes for managing its working capital, its financial risk management objectives and its exposure to credit and liquidity risks.
In particular, the directors have considered the challenges from the macro environment on international business, and the general inflationary pressure on costs. The Company did not see any impact on the supply chain of its raw materials or its products but did observe reduced demand for TMT® and for its services during the second half of 2023 but has seen first signs of a potential recovery since the beginning of 2024. During 2023 the Company has observed price increases from its suppliers and vendors and had increases in its labour costs.
Due to the continued backdrop from the macro environment on international business, and the general inflationary pressure on costs, Group revenues for the year ended 31 December 2023 decreased by 35% to £5.03m (2022: £7.78m). Proteomic (biomarker) services decreased 41% to £1.63m (2022: £2.75m). Sales and royalties attributable to TMT® and TMTpro™ reagents were £3.40m (2022: £4.16m). Total costs, excluding finance costs, rose to £6.65m (2022: £6.05m) and this resulted in an operating loss of £1.62m (2022: operating profit of £1.73m) and a net loss of £2.44m (2022: a profit of £1.33m). Cash reserves at the year-end were at £2.03m (2022: £3.99m).
The Group is also dependent on the loan facility provided by the Chairman of the Group, which under the terms of the facility, is repayable on demand. The amount owed as of 31 December 2023, including interest, was £11,235k (2022: £10,459k).
이사들은 상환을 요구할 의사가 없으며 승인일로부터 최소 12개월 동안 기존 조건에 따라 그룹에 계속해서 혜택을 제공할 수 있다는 법적 구속력이 있는 서면 확인서를 의장으로부터 받았습니다. 본 재무제표 또는 최소 30년 2025월 XNUMX일까지.
29년 2021월 1일, Vulpes Investment Management Private Limited("VIM")("대출")의 대출 제도가 개정되어 대출금과 발생한 모든 이자가 이제 2022년 1월 2021일(이전 17년 2021월 XNUMX일)에 상환 가능해졌습니다. XNUMX년 XNUMX월 XNUMX일에 일반 대출로의 전환을 허용하도록 대출 계약이 수정되었습니다. shares such that until 30 April 2022, VIM may convert part (being not less than £50,000 or a multiple thereof) or all of the Drawn Loan and accrued interest to 31 December 2022 (being £51,538) into new ordinary shares of the Company. The conversion price was 7.16p per share, which is the average of the closing middle market price for the ordinary shares of the Company during the five consecutive trading days immediately prior to entering into the Loan Amendment. of On 30 March 2022, the Company signed the Third Amendment to the VIM Loan Agreement which extended the term of the loan to 30 June 2023. At 31 May 2023 amounts drawn £700k interest £102k). The loan and accrued interest totalling £824,424 was repaid to VIM on the 1 June 2023.
예측, 예산, 판매 주문서를 자세히 검토하고 글로벌 팬데믹 이후 XNUMX년차에 그룹이 어떻게 거래했는지에 대한 지식을 바탕으로 이사들은 그룹 전체가 다음을 수행할 수 있는 적절한 재정 및 기타 자원을 가지고 있다고 합리적으로 기대합니다. 이 재무제표 승인 후 최소 XNUMX개월 동안 계속 운영됩니다. 이러한 이유로 이사들은 재무제표 작성 시 계속기업 원칙을 계속해서 채택하고 있습니다.
3. 계속 운영으로 인한 주당 이익
보통주당 기본손실과 희석손실의 계산은 다음의 이익과 주식수를 기준으로 이루어졌습니다.
|
| 2023 | 2022 | |
|
| £'000 | £'000 | |
회계연도의 (손실)/이익 | (2,443) | 1,325 | ||
| 2023 수 | 2022 수 | ||
기본주당이익과 희석주당이익 계산을 위한 가중평균보통주식수: 희석주당순이익 계산을 위한 가중평균 보통주 및 미발행옵션 수: |
295,182,056
311,222,086 |
295,182,056
309,020,565 |
The weighted average number of ordinary shares outstanding was calculated applying the treasury stock method to an amount of 23.6m share options which were in the money at the 31 December 2023. An average share price for 2023 of 5.43p per share added by the outstanding service amounts for these options and resulting in a number of shares of 16,040,030 added to the existing issued share stock for the purpose to calculate the diluted EPS. A number of 0.5m shares were not considered in the calculation of the weighted number of outstanding shares used for the diluted EPS calculation as these options were not dilutive at the 31 December 2023. Since the Group is recording a loss for 2023 no dilution has been recognised in calculation of the loss per share for 2023.
4. 미래예측진술에 대한 주의사항
Proteome Sciences는 이번 예비 발표에서 미래 예측 진술을 했습니다. 그룹은 역사적 사실이 아닌 모든 진술을 "미래 예측 진술"로 간주합니다. 이는 실제 결과와 그룹의 재무 성과가 미래 예측 진술에 포함된 내용과 실질적으로 달라질 수 있는 위험과 불확실성에 영향을 받는 사건 및 추세와 관련됩니다. 이러한 진술은 이용 가능한 정보를 바탕으로 선의로 작성되었으며, 그러한 진술은 경제적, 사업적 위험 요소를 포함한 내재된 불확실성으로 인해 주의 깊게 다루어야 합니다.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.